Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Bacteria (1)
- Bacterial Infections and Mycoses (1)
- Biochemical Phenomena, Metabolism, and Nutrition (1)
- Chemical and Pharmacologic Phenomena (1)
- Complex Mixtures (1)
-
- Digestive System Diseases (1)
- Digestive, Oral, and Skin Physiology (1)
- Diseases (1)
- Gastroenterology (1)
- Infectious Disease (1)
- Laboratory Medicine (1)
- Medical Biochemistry (1)
- Medical Education (1)
- Medical Microbiology (1)
- Medical Pharmacology (1)
- Medical Sciences (1)
- Medical Specialties (1)
- Medicinal and Pharmaceutical Chemistry (1)
- Organisms (1)
- Other Chemicals and Drugs (1)
- Patient Safety (1)
- Pharmacy and Pharmaceutical Sciences (1)
- Public Health (1)
Articles 1 - 2 of 2
Full-Text Articles in Pharmaceutical Preparations
Oral Dosages Of The Nsaid Aspirin Decreased The Growth Rate Of Species Found In The Human Gut Microbiome Including Akkermansia Muciniphila, Bacteroides Fragilis, Clostridium Sordellii, And Clostridium Difficile, Wyatt H. Greenbaum, Garrett J. Greenbaum, Anna Spiezio
Oral Dosages Of The Nsaid Aspirin Decreased The Growth Rate Of Species Found In The Human Gut Microbiome Including Akkermansia Muciniphila, Bacteroides Fragilis, Clostridium Sordellii, And Clostridium Difficile, Wyatt H. Greenbaum, Garrett J. Greenbaum, Anna Spiezio
PANDION: The Osprey Journal of Research and Ideas
Over past few decades, new insight has been revealed in the scientific community about the importance of the human gut microbiome relating to general health. It is known that imbalances in the species that reside in the human gut can cause organism-wide problems in humans. When prescribing or injecting oral medications, the thought of the downstream effects on the gut microbiome are not always considered. By exposing known healthy members of the gut; Akkermansia muciniphila, Bacteroides fragilis, Clostridium sordellii, and Clostridium difficile to the Aspirin, this study attempted to provide insight into the effects of the drug on bacterial growth. …
There Is A Trend Favoring Vancomycin Vs. Metronidazole In Treating Severe C. Difficile Infection, Dean D. Fouchia
There Is A Trend Favoring Vancomycin Vs. Metronidazole In Treating Severe C. Difficile Infection, Dean D. Fouchia
Clinical Research in Practice: The Journal of Team Hippocrates
A critical appraisal and clinical application of Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345-354. doi: 10.1093/cid/ciu313